Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5842 USD | +6.86% | +2.31% | -44.89% |
21/03 | Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
15/03 | Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1.63M 136M | Sales 2025 * | 13.61M 1.13B | Capitalization | 4.43M 369M |
---|---|---|---|---|---|
Net income 2024 * | -16M -1.33B | Net income 2025 * | -11M -917M | EV / Sales 2024 * | 2.72 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.33 x |
P/E ratio 2024 * |
-0.19
x | P/E ratio 2025 * |
-0.25
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.45% |
Latest transcript on Ensysce Biosciences, Inc.
1 day | +6.86% | ||
1 week | +2.31% | ||
Current month | -26.07% | ||
1 month | -28.67% | ||
3 months | -62.79% | ||
6 months | -45.40% | ||
Current year | -44.89% |
Managers | Title | Age | Since |
---|---|---|---|
D. Kirkpatrick
CEO | Chief Executive Officer | 67 | 01/09/01 |
David Humphrey
DFI | Director of Finance/CFO | 55 | 01/21/01 |
Jeffrey Millard
COO | Chief Operating Officer | 49 | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Martin
BRD | Director/Board Member | 63 | 01/20/01 |
D. Kirkpatrick
CEO | Chief Executive Officer | 67 | 01/09/01 |
Bob Gower
CHM | Chairman | 86 | 01/08/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.5842 | +6.86% | 176,560 |
25/24/25 | 0.5467 | -2.13% | 59,748 |
24/24/24 | 0.5586 | +0.05% | 42,999 |
23/24/23 | 0.5583 | +3.20% | 43,903 |
22/24/22 | 0.541 | -5.25% | 53,698 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.89% | 4.43M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENSC Stock